UroGen Pharma draws $25M Tranche C loan under credit facility

UroGen Pharma Ltd.

Received $25M third tranche loan on Sept 23, 2024; proceeds for general corporate and working capital needs.
Interest rate: 3-month SOFR + 7.25% + 0.26161% p.a., floor 2.50%, payable quarterly.
Matures Mar 16, 2027, extended to Mar 16, 2028 if FDA approves UGN-102 by June 30, 2025.
Repayment in four equal quarterly installments starting June 30, 2026 (or June 30, 2027 if FDA condition met).
Loan is secured by substantially all of the credit parties' tangible and intangible assets.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.